Many therapeutic monoclonal antibodies (MAbs) with various indications have been approved by the U.S. Food and Drug Administration and hundreds of MAbs are currently in various stages of development. Following the approval of the first humanized therapeutic antibody in 1997, the humanized antibodies trastuzumab (Herceptin) and bevacizumab (Avastin) have gone on to achieve blockbuster status. 1) Aggregation compromises the safety and efficacy of therapeutic proteins. For example, the intravenous (i.v.) injection of aggregated proteins can cause shock in patients, and aggregated antibodies are known to raise anti-idiotypic antibodies that lower the activity of therapeutic antibodies. [2] [3] [4] During their production, antibody solutions that contain a large percentage of aggregates cause the fouling of antiseptic filters and result in poor productivity.
Subcutaneous (s.c.) administration is the preferred route because this method requires a shorter time than i.v. infusion, and self-administration by patients at home is possible. For s.c. administration, a high concentration solution of MAbs is necessary because a large dose (100-200 mg) is required for treatment; however, the injection volume is limited (Ͻ1.5 ml).
5) The development of a high-concentration MAb formulation is very challenging because proteins in highly concentrated solutions tend to self-associate. 6) During their production, purification, and storage, therapeutic proteins are subject to aggregation. 7) Especially during the purification process, acid-induced conformational changes of MAbs are inevitable during their elution from protein-A resin at a low pH. 8, 9) To prevent this problem, various approaches have been developed, e.g., milder elution conditions, 10) low affinity matrices, 11, 12) and the addition of anti-aggregating reagents such as arginine. [13] [14] [15] [16] One of the major analytical methods for the quality evaluation of MAbs is size-exclusion chromatography (SEC); this method is able to detect MAb aggregates and degradates. In recent years, new analytical methods have been reported that use markers of amyloid-like properties, and several commercially available biopharmaceutical products were found to contain misfolded proteins with amyloid-like properties. 17) In some cases, the level of misfolded protein was found to increase upon storage under the conditions prescribed by the manufacturer.
On the other hand, the mechanisms of aggregate formation are largely unknown. Accumulating experimental data show that proteins, especially ones with amyloidogenic properties, often contain specific sequences or structural motifs that tend to promote aggregation. Wang et al. studied the sequences and fragment antigen-binding (Fab) structures of antibodies for their vulnerability toward aggregation by using sequencebased computational tools to identify potential aggregationprone motifs. Some of these motifs are located in variable domains, primarily in complementarity-determining regions (CDRs).
18) The implication is that one possible mechanism for MAb aggregation may be through the formation of crossb structures and fibrils.
We incidentally obtained an anti-dinitrophenol (DNP) antibody that was highly prone to aggregation. We reasoned that this antibody would be useful to develop various approaches anti-DNP1 exhibited a much higher aggregate content (dimer or trimer) than anti-DNP2 when analyzed by size-exclusion chromatography (SEC). As anti-DNP1 had a longer complementarity-determining region 3 (CDR3) light chain than anti-DNP2 by 2 amino acid residues, we hypothesized that the increased aggregation of DNP1 was due to these extra residues; therefore, we prepared mutant antibodies with shorter CDR3s to compare their aggregation properties. Anti-DNP1-D DEI, with the same CDR3 length as anti-DNP2, exhibited no aggregates as expected. Anti-DNP1-D DI, with 1 additional residue, exhibited a smaller peak than wild-type (WT) in SEC, whereas this mutant exhibited stronger thioflavin T fluorescence than WT, which is indicative of amyloid formation. In addition, the anti-DNP1-D DI solution (but not others) became opalescent at 4°C and exhibited large visible particles, which are undetectable by SEC. The fragment antigen-binding region of this mutant was found to have lower thermal stability than the others by differential scanning calorimetry. These data suggest that diverse analytical methods should be applied to evaluate MAb aggregation, in addition to the commonly used SEC.
Evaluation of the Aggregation States of Monoclonal Antibodies by Diverse and Complementary Methods
to prevent the MAb aggregation. As sequence analyses of this MAb indicated that it had a longer CDR3 than a non-aggregating MAb, we constructed mutant antibodies with a shorter CDR3 to compare their aggregation characteristics. In the present paper, diverse analytical techniques were extensively employed to evaluate the aggregation of anti-DNP antibodies.
MATERIALS AND METHODS

Materials
The immunoglobulin G1 (IgG1) antibodies (anti-DNP1 (wild-type; WT), anti-DNP1-DE, anti-DNP1-DI, anti-DNP1-DEI, and anti-DNP2) were expressed by Chinese hamster ovary cells and purified with protein A (Amersham Biosciences Corp., Piscataway, NJ, U.S.A.) as described previously. 19) Antibodies were diluted in phosphate-buffered saline (PBS; Gibco Industries Inc., Langley, OK, U.S.A.) at pH 7.2, unless otherwise specified. Thioflavin T (ThT) was from Calbiochem (San Diego, CA, U.S.A.). The other reagents were of analytical grade.
Size-Exclusion Chromatography The amounts of small soluble aggregates were analyzed by SEC-HPLC (LC-7A, Shimadzu Corp., Kyoto, Japan) with a G3000SW XL column (7.8 mm i.d.ϫ30 cm; Tosoh Corp., Tokyo, Japan) essentially as described previously. 20) The mobile phase contained 20 mM sodium phosphate (pH 7.0) and 500 mM sodium chloride. The experimental conditions were as follows: injected protein, 20 mg; flow rate, 0.5 ml/min; detection wavelength, 215 nm; and analysis time, 30 min.
Thioflavin T Fluorescence Measurement To determine possible amyloid formation by the antibodies, fluorescence emission spectra of ThT (450-600 nm) were measured on a Jasco FP-6500 Spectrofluorometer with an excitation wavelength at 440 nm at room temperature (ca. 25°C). Antibody solutions were diluted in 3 ml PBS supplemented with 10 mM ThT and 20 mM Tris-HCl buffer (pH 7.4), and incubated for 60 min at 37°C.
Dynamic Light Scattering (DLS)
The size distribution of the microparticles in the antibody solutions were determined more precisely using a DLS photometer (Zeta Sizer Nano-ZS equipped with a He-Ne laser; Malvern Instruments Ltd., Worcestershire, U.K.). Scattered light intensity was detected at an angle of 173°. The samples were analyzed at 4°C or 37°C without prior filtration.
Differential Scanning Calorimetry (DSC) The thermal stability of the antibodies was analyzed using a VP-DSC differential scanning calorimeter (MicroCal, Piscataway, NJ, U.S.A.). Antibody samples (1 mg/ml) were analyzed at 5-95°C with a heating rate of 1°C/min.
RESULTS
Characterization of MAbs by SEC
We expressed 2 different anti-DNP MAbs found in our laboratory at high levels in Chinese hamster ovary cells. One antibody (hereafter designated as anti-DNP1) exhibited a high content (ca. 8%) of small aggregates (dimer or trimer), whereas the other (anti-DNP2) exhibited negligible aggregates when analyzed by SEC at ambient temperatures. To identify the particular amino acid sequence that lead to the high aggregation tendency of anti-DNP1, we compared the sequences of the heavy and light chains from both antibodies.
Sequence alignment (Fig. 1 ) revealed that these 2 antibodies differed from each other in the length of the CDR3 light chain, but not in the length of CDR1 or CDR2. There were 2 extra amino acids in the anti-DNP1 CDR3, and we hypothesized that its length affects the aggregation propensities of antibodies. Hence, we generated 3 different mutant anti-DNP1 antibodies: anti-DNP1-DI, in which the hydrophobic isoleucine residue (which is expected to enhance protein aggregation) was deleted; anti-DNP1-DE, in which the glutamate residue flanking the isoleucine residue was deleted; and anti-DNP1-DEI in which these isoleucine and glutamate residues were deleted.
As expected, anti-DNP1-DEI, with the same CDR3 length as anti-DNP2, exhibited no (Ͻ0.4%) aggregates (Fig. 2) . Anti-DNP1-DI, with 1 extra amino acid in the CDR3 compared to anti-DNP2, exhibited intermediate aggregate content (3.9%) between WT (7.0%) and anti-DNP1-DEI. However, deletion of glutamate (anti-DNP1-DE) increased aggregate content to as much as 14.2%, even though this mutant had the same CDR3 length as anti-DNP1-DI.
Evaluation of Antibody Aggregation with an AmyloidReactive Reagent In addition to SEC, we evaluated antibody aggregation by fluorescence spectroscopy, which can be conducted more efficiently than SEC. ThT exhibits strong fluorescence on specific binding to amyloid fibrils, such as those of amyloid b-peptides and b 2 -microglobulin, and can be used to quantify amyloid levels. 21, 22) Anti-DNP1 (WT) exhibited fluorescence at ca. 480 nm, which is characteristic of amyloid (Fig. 3) . This observation indicates that the anti-DNP1 (WT) aggregates have some amyloid characteristics. Anti-DNP1-DEI exhibited little enhancement compared with buffer (negative control), as expected from the negligible amounts of aggregates observed by SEC. Anti-DNP1-DE exhibited fluorescence at a slightly lower level than WT, although the former exhibited higher aggregate content than the latter when analyzed by SEC. These observations suggest that the WT oligomers had a somewhat stronger tendency to elongate into larger amyloid fibrils than anti-DNP1-DE. On the other hand, anti-DNP1-DI exhibited much larger fluorescence (ca. 2-fold) than WT in spite of its much lower aggregate content (approximately half) than WT when analyzed by SEC. These observations suggest that anti-DNP1-DI contains large particles that are not detectable with SEC, and that these particles were sensitively detected by ThT fluorescence.
Low-Temperature-Induced Reversible Aggregates of Anti-DNP1-D DI During the preparation of the 4 antibody samples, we noticed that the anti-DNP1-DI solution became opalescent immediately after purification at 4°C, and that this opalescence was clearly reversible at ambient temperatures. The other antibody solutions remained clear, irrespective of temperature. To analyze these phenomena in more detail, we measured the turbidity of the antibody solutions. The anti-DNP1 (WT), anti-DNP1-DE, and anti-DNP1-DEI (1 mg/ml) solutions exhibited null turbidity at 600 nm on ice.
On the other hand, the anti-DNP1-DI solution exhibited a turbidity of 1.22 under the same condition. Immediately after incubation at 37°C, the turbidity of the anti-DNP1-DI solution started to decrease with a half-life of ca. 1 min; the turbidity was 0.04 at 5 min (Fig. 4) . The turbidity of the solution returned to 1.18 after incubation on ice for 15 min. Thus, anti-DNP1-DI formed reversible aggregates at low temperatures.
Size Distribution of Antibody Aggregates as Analyzed by DLS SEC is an authentic analytical method for determining aggregate content in immunoglobulin G (IgG) solutions; monomers with a diameter of ca. 10 nm elute well sep- 
Fig. 4. Turbidity Decrease of Anti-dinitrophenol (DNP)1-DI Solution on Warming
Ice-cold solution of anti-DNP1-DI (1 mg/ml in phosphate-buffered saline) was warmed at 37°C and its turbidity at 600 nm was measured at the indicated times. The right-most data point indicates the turbidity of the solution that was re-chilled for 15 min on ice.
arated from dimers and trimers. 6, 20) However, SEC is not applicable to the detection of much larger aggregates. The aggregates of anti-DNP antibodies were investigated by DLS measurements, which give information on the size distribution from monomers (10 nm) to large aggregates (1000 nm). Since we observed that the turbidity of the solution (anti-DNP1-DI) changed by incubation at 37°C, we analyzed the diameter distributions of the 4 antibodies by DLS at 4°C and 37°C.
Anti-DNP1 (WT) exhibited 2 peaks at 37°C: 1 peak at ca. 14 nm, as expected from the hydrodynamic diameter of IgG monomers, and the other at ca. 78 nm, corresponding to aggregates much larger than dimers or trimers (Fig. 5A) . The scattering intensity of the peak at 78 nm was higher than that of the monomeric peak. At 4°C, the positions of the 2 peaks remained unchanged, but the relative intensity of the aggregates increased. It should be noted, in DLS measurements, that dimers and trimers cannot be observed as a single peak separate from monomers and that they contribute to the intensity of the peak corresponding to the monomers.
Anti-DNP1-DEI also exhibited 2 peaks at 37°C; however, the intensity of the aggregates (with a diameter of 185 nm) was much lower than for WT (Fig. 5D ), in agreement with the low aggregate content of the mutant as observed by SEC and ThT fluorescence measurements. The size distribution remained unchanged at 4°C. Anti-DNP1-DE exhibited a similar size distribution as anti-DNP1-DEI, except that the diameter of the aggregates was larger (380 nm; Fig. 5B ).
Anti-DNP1-DI exhibited no aggregate peak in the 70-1000 nm range at 37°C (Fig. 5C) , in contrast to the other antibodies. However, this mutant generated huge particles whose size could not be evaluated accurately by DLS measurements. Interestingly, at 4°C, this mutant exhibited a single peak at ca. 1100 nm, but no peak corresponding to the monomer. This observation was in agreement with the high turbidity of the mutant at a low temperature and suggests that anti-DNP1-DI has different aggregation mechanisms from the other antibodies.
Stability Analysis by DSC Anti-DNP1-DI is expected to have lower temperature stability because this mutant greatly changes its aggregation state depending on the temperature. We analyzed the temperature stability of our antibodies by DSC, which provides information on the stability of each domain in a multi-domain protein, such as antibodies. The effects of the length of CDR3 on the stability of Fab were also of interest.
Each thermogram of anti-DNP1 (WT), anti-DNP1-DE, and anti-DNP1-DEI consisted of 2 transitions, centered at ca. 70°C and 83°C (Fig. 6 ). For these antibodies, the first transition had a larger amplitude than the second one. These thermograms are similar to those for the humanized monoclonal antibody bevacizumab against vascular endothelial growth factor (Avastin) 23) and a murine IgG2a antibody against HIV- 1 capsid protein p24 (CB4-1).
8) The first and second transitions were assigned, respectively, to the unfolding of the Fab and fragment crystallizable (Fc) regions by DSC analyses of each fragment. For anti-DNP1-DEI, the first transition was increased by 3°C compared with the WT, which indicates the increased stability of Fab (and CH2) by the deletion of the 2 residues. This observation is in good agreement with the low aggregate content of this antibody.
For anti-DNP1-DI, the thermogram exhibited an extra peak at 58°C compared with the other antibodies. The decrease in the intensity of this peak at 70°C and its concomitant emergence at 58°C indicate that the latter peak is ascribed to Fab and the former one to CH2. The lower unfolding temperature of Fab in anti-DNP1-DI indicates that the deletion of the isoleucine residue destabilized the Fab. These observations confirm that the first large transition of anti-DNP1 (WT), anti-DNP1-DE, and anti-DNP1-DEI corresponds to the Fab and CH2 fragments. On the other hand, the second transition (CH3) remained unchanged for all antibodies, suggesting that the stability of Fab (and CH2) does not affect that of CH3.
Characterization of Anti-DNP Antibodies by Light Microscopy To further characterize the large particles found in the anti-DNP1-DI solution at low temperatures, antibody solutions were analyzed by light microscopy. Anti-DNP1-DI exhibited many particles as large as 50 mm in diameter (Fig.  7A) . Although we expected fibrillar structures from the high ThT fluorescence of this mutant, the particles were amorphous. These particles disappeared almost completely after incubation at 37°C for 10 min (Fig. 7B) . No particles were observed for anti-DNP1 (WT), anti-DNP1-DE, and anti-DNP1-DEI, irrespective of temperature (data not shown), as expected from their turbidity and DLS measurements.
DISCUSSION
The high aggregation property of the anti-DNP1 antibody was eliminated by deleting the 2 extra residues (EI) in its CDR3 light chain compared with that of anti-DNP2, which exhibited low levels of aggregation. Adjusting the length of the CDR3 light chain may therefore represent an effective technique for preventing antibody aggregation.
However, the length of CDR3 may not be the sole determinant of the aggregation property because anti-DNP1-DE and anti-DNP1-DI, with the same CDR3 length (1 extra residue compared to anti-DNP2), exhibited quite different aggregation behavior: anti-DNP1-DE and anti-DNP1-DI, respectively, exhibited a larger and smaller dimer/trimer peak than WT in SEC, whereas they had lower and higher amyloid properties than WT. Anti-DNP1-DI, but not anti-DNP1-DE, formed large visible particles at low temperatures. These different behaviors may be related to the lower thermal stability of anti-DNP1-DI as revealed by DSC.
The different aggregation properties of the anti-DNP antibodies and their mutants will serve as good models for the analysis of the aggregation mechanisms of MAbs and the development of effective methods/reagents that prevent antibody aggregation.
In addition to the authentic SEC method, we evaluated the aggregation of anti-DNP antibodies by diverse analytical methods: SEC, DLS, DSC, turbidity, light microscopy, and ThT fluorescence. Although SEC is quite useful for determining dimer/trimer content, this method cannot detect aggregates larger than 100 Å. For the evaluation of large aggregates, DLS can be used to obtain information on their size distribution, although not in a high-throughput fashion. An alternative means to analyze large aggregates would be ThT fluorescence measurement, which can be conducted in a high-throughput manner by using microplate readers. 24) In fact, anti-DNP1-DI, which showed a lower dimer/trimer content than WT and anti-DNP1-DE, had higher ThT fluorescence levels than these antibodies, and this discrepancy in antibody behavior prompted us to analyze their size distribution by DLS. DSC was another useful method that can also be conducted in a high-throughput manner. This method can detect antibodies with low thermal stability that have potential aggregation properties. It should also be noted that analyses at multiple temperatures (e.g., 4, 37°C) provides important information that cannot be obtained at a single temperature, e.g., the high aggregation properties of anti-DNP1-DI were not observed at 37°C. We evaluated the aggregation properties of anti-DNP antibodies with different methods and found that all of the DLS, ThT fluorescence, and DSC analyses consistently suggest the high aggregation property of anti-DNP1-DI, in contrast to the SEC analysis. Thus, at least ThT fluorescence analysis should be executed concurrently with SEC one, taking advantage of its ability to be done efficiently with microplate readers. Nevertheless, we recommend that the exhaustive analyses as carried out in this study should be conducted, especially during the early stages of therapeutic MAb development. 
